Ian Eliason
Principal, Strategy & Operations @ Zoic Capital
Ian Eliason is a seed investor at Zoic Capital focused on Health Care and Biotechnology. Naturally, entrepreneurial Ian has been with Zoic since its inception in 2014, when it was little more than a concept on the back of a napkin. He helped develop the investment strategy, build the deal flow network, and constructed the operational infrastructure necessary to launch then manage institutional level capital. Within his role at ZoicIan has evaluated over 1,000 life sciences companies, and he plays a key role in the firm’s investment decisions including deal selection and structuring.If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to exchange good reads and travel ideas, send me an email: ian@zoiccapital.com
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Ian Eliason invests in
Stages Ian Eliason invests in
Countries Ian Eliason invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 4 (80%)
- Health Diagnostics 2 (40%)
- Medical 1 (20%)
- Robotics 1 (20%)
Stage
- Seed 3 (60%)
- Series A 1 (20%)
- Convertible Note 1 (20%)
Country
- United States 4 (80%)
- Canada 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ProbiusDx is an electronic sensing company that provides a diagnostic technology for detecting and monitoring blood concentrations. | $7.2M / Series A / Dec 01, 2020 | ||
| HDT Bio is a developer of RNA vaccines and therapeutics based on LION formulation technology. The company's technology platforms and products cover a wide range of immunotherapy modalities and mechanisms of action, including innate immunity activation, adaptive immune response amplification, and tumor-tight junction disruption. Its mission isto maintain the rapid and significant progress made in the fight against the world's deadliest infectious diseases by developing cutting-edge immunotherapy technologies in a cost-effective manner across leading markets as well as low or middle-income countries. | $4M / Seed / Oct 05, 2020 | ||
| BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders. The company was founded in 2018 and is based in Belmont, Massachusetts. | Convertible Note / Jul 02, 2020 | ||
| ODS Medical Inc. is a medical device company that seeks to commercialize their exclusive Raman spectroscopy system for real-time detection of tissue abnormalities through the development, manufacture and sales of products for a range of clinical settings.ODS Medical Inc. is dedicated to bringing to the hands of physicians the next generation ofdiagnostic tools. Building on our revolutionary proprietary platform technology, we integrate cutting edge optical probes with the most sophisticated software, based on machine learning algorithms, to empower doctors to make critical decisions- in real-time - with unprecedented sensitivity, specificity and accuracy. | Seed / Jun 01, 2020 | ||
| Juno Diagnostics is a health technology company democratizing access to high-value genetic information. The company is developing simple, cost-effective devices that enable point-of-need genetic testing. It was founded in 2017 and is based in San Diego, California. | Seed / Jan 01, 2019 |
Co-Investors
About Zoic Capital
Zoic Capital is the only US-based venture firm focused on early-stage healthcare innovations at the intersection of life sciences and medical technology.Promising Scientific Advancements: We look for breakthroughs with the potential for broad IP and commercial-ready maturity. We invest in roadmaps that leverage a core innovation across manyapplications and industries.Focus on Life Sciences: We see the most exciting advancements coming from life sciences labs, becoming tools that maintain and treat our health. We look at both technologies that enable development and care delivery devices.We Follow the Numbers: We follow our gut, but we also reinforce each of our decisions with numbers. We believe that merging qualitative and quantitative analysis is the best way to make successful investment decisions.Mentored Capital: We have the skills, experience and network to help, working closely with select teams to transform research into high impact, market-ready products.Milestone-Based Investing: We craft unique deal structures for each portfolio company based on mutually defined milestones. We find this approach creates ongoing momuntum and sets us all up for success.
Zoic Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ian Eliason
Principal, Strategy & Operations
|
|||
Ann Revell-Pechar
Communications Director
|
|||
Lahav Gil
Venture Partner
|
|||
Neal Mody
Partner & Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Ian Eliason invest in?
Ian Eliason invests primarily in Health Care, Biotechnology and Health Diagnostics startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ian Eliason?
Public channels for Ian Eliason include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ian Eliason last invest?
The most recent investment recorded for Ian Eliason closed in Dec 2020. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
